Achieved an ORR of 50% in one study in CCR4+ PTCLAchieved an ORR of 34% in another study, with no significant correlation between CCR4 expression levels and response ratesAssociated with a high frequency of adverse events, particularly neutropenia and lymphopenia. This evidence concerns the gene CCR4 and neutropenia.